Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ajh.26333 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characterizing second line and beyond therapies for primary central nervous system lymphomas.
Hematol Oncol
November 2024
The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Article Synopsis
- Primary central nervous system lymphoma (PCNSL) is a rare and aggressive cancer affecting the brain and spinal cord, typically treated with high-dose methotrexate (HDMTX) combined with other therapies, but many patients relapse after initial treatment.
- A study analyzed 54 adult PCNSL patients who received HDMTX-based treatment from 2016 to 2022, revealing that 57% underwent consolidation therapy, while 24% had autologous stem cell transplants.
- For those with relapsed or refractory (R/R) disease, treatments varied widely, including second and third line options like whole brain radiation (WBRT), clinical trials, and various combinations of rit
Cost and value of cancer medicines in a single-payer public health system in Ontario, Canada: a cross-sectional study.
Lancet Oncol
April 2024
Division of Cancer Care and Epidemiology, Queen's Cancer Research Institute, Kingston, ON, Canada; Department of Oncology, Queen's University, Kingston, ON, Canada; Public Health Sciences, Queen's University, Kingston, ON, Canada. Electronic address:
Background: The financial impact of cancer medicines on health systems is not well known. We describe temporal trends in expenditure on cancer medicines within the single-payer health system of Ontario, Canada, and the extent of clinical benefit these treatments offer.
Methods: In this cross-sectional study, we identified cancer medicines and expenditures from formularies and costing databases (the New Drug Funding Program, Ontario Drug Benefit Program, and The High-Cost Therapy Funding Program) during 10 consecutive years (April 1, 2012, to March 31, 2022) in Ontario, Canada.
Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study.
Leuk Lymphoma
January 2023
Siteman Cancer Center, Washington University, St. Louis, MO, USA.
The multicohort phase 1b KEYNOTE-013 study (NCT01953692) evaluated the safety and efficacy of pembrolizumab in patients with relapsed or refractory NHL who were ineligible for or failed hematopoietic cell transplantation (HCT). Patients received pembrolizumab (cohort 4) or pembrolizumab plus lenalidomide (cohort 5). Primary end points were safety and objective response rate (ORR) per IWG 2007 criteria.
View Article and Find Full Text PDFAnalyses of Ocular Adverse Reactions Associated With Anticancer Drugs Based on the Japanese Pharmacovigilance Database.
Anticancer Res
September 2022
Department of Clinical Pharmacy, Fujita Health University School of Medicine, Toyoake, Japan.
Background/aim: The systemic administration of anticancer drugs may cause ocular adverse reactions (OARs). However, such adverse events are generally rare and occur with an unknown frequency. This study aimed to investigate the tendency of occurrence of OARs induced by systemic anticancer drugs using a large spontaneous pharmacovigilance database in Japan.
View Article and Find Full Text PDFPembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma.
Am J Hematol
November 2021
John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, New Jersey, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!